We propose that FAP‐targeted immunotherapy could be a more effective approach to targeting the glioblastoma vasculature by facilitating the rapid and selective physical destruction of existing tumor blood vessels, including their supporting perivascular network, rather than aiming to block a pro‐angiogenic signalling pathway that tumors can evolve to survive without. Here, FAP is linked to glioblastoma.